Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be6A Lung-01: sigvotatug vedotin vs docetaxel in previously treated NSCLC
2023-503827-25-01Phase 3Authorised
- Sponsor
- Seagen Inc.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of sigvotatug vedotin in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Seagen Inc. Primary endpoint: Overall survival. Planned start Dec 2023; status: authorised.
02
Drugs
sigvotatug vedotin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2023-503827-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503827-25-01.